Key result
Compared to patients with coronary heart disease, patients with stroke had higher odds of not being prescribed recommended secondary prevention medications (adjusted OR 1.37; 95% CI 1.31-1.44).
Why the study?
To compare secondary prevention care between patients with coronary heart disease and stroke, specifically examining the influence of primary care visit frequency and regularity.
Are patients with stroke less likely to receive recommended secondary prevention medications and risk factor assessments compared to patients with coronary heart disease?
Cross-Sectional (n=149,546)
Yes
Are patients with stroke less likely to receive recommended secondary prevention medications and risk factor assessments compared to patients with coronary heart disease?
Odds Ratio: 1.37 (95% CI 1.31–1.44)
Secondary prevention management is suboptimal in cardiovascular disease patients and significantly worse post-stroke compared with post-CHD in Australian primary care.
OBJECTIVES: To compare secondary prevention care for patients with coronary heart disease (CHD) and stroke, exploring particularly the influences due to frequency and regularity of primary care visits. SETTING: Secondary prevention for patients (≥18 years) in the National Prescription Service administrative electronic health record database collated from 458 Australian general practice sites across all states and territories. DESIGN: Retrospective cross-sectional and panel study. Patient and care-level characteristics were compared for differing CHD/stroke diagnoses. Associations between the type of cardiovascular diagnosis and medication prescription as well as risk factor assessment were examined using multivariable logistic regression. PARTICIPANTS: Patients with three or more general practice encounters within 2 years of their latest visit during 2016-2020. OUTCOME MEASURES: Proportions and odds ratios (ORs) for (1) prescription of antihypertensives, antilipidaemics and antiplatelets and (2) assessment of blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in patients with stroke only compared against those with CHD only and those with both conditions. RESULTS: There were 111 892 patients with CHD only, 27 863 with stroke only and 9791 with both conditions. Relative to patients with CHD, patients with stroke were underprescribed antihypertensives (70.8% vs 82.8%), antilipidaemics (63.1% vs 78.7%) and antiplatelets (42.2% vs 45.7%). With sociodemographic factors, comorbidities and level of care considered as covariates, the odds of non-prescription of any recommended secondary prevention medications were higher in patients with stroke only (adjusted OR 1.37; 95% CI (1.31, 1.44)) compared with patients with CHD only. Patients with stroke only were also more likely to have neither BP nor LDL-C monitored (adjusted OR 1.26; 95% CI (1.18, 1.34)). Frequent and regular general practitioner encounters were independently associated with the prescription of secondary prevention medications (p<0.001). CONCLUSIONS: Secondary prevention management is suboptimal in cardiovascular disease patients and worse post-stroke compared with post-CHD. More frequent and regular primary care encounters were associated with improved secondary prevention.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2023) conducted a cross-sectional in Coronary heart disease and stroke (n=149,546). Stroke vs. Coronary heart disease was evaluated on Non-prescription of any recommended secondary prevention medications (OR 1.37, 95% CI 1.31-1.44). Compared to patients with coronary heart disease, patients with stroke had higher odds of not being prescribed recommended secondary prevention medications (adjusted OR 1.37; 95% CI 1.31-1.44).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: